Esperion Therapeutics, Inc. (ESPR)
As-reported financials and SEC filings for Esperion Therapeutics, Inc. The latest annual period is FY2025. The latest reported quarter is Q1 FY2026. Financial statements come straight from the company’s EDGAR filings; valuation figures such as P/E and market cap use market data.
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines to reduce low-density lipoprotein cholesterol (LDL-C) and cardiovascular risk. Its main products include NEXLETOL and NEXLIZET, which are approved for patients at risk for cardiovascular disease who are unable or unwilling to take statins. The company serves adults with elevated LDL-C, including those with established cardiovascular disease or at high risk for cardiovascular events.
Snapshot
Fundamentals are from SEC filings for FY2025, the latest annual period (ended December 31, 2025). P/E and market cap are derived from stored market prices, last retrieved on a rolling basis and typically within the past week.
What changed at Esperion Therapeutics
- Revenue grew 21.3% to $403M in FY2025, slower than the 185.7% the year before.
- Operating margin turned positive at 15.0% in FY2025, from a 289.0% operating loss in FY2021.
- Most recent quarter Q1 FY2026: revenue $80M, up 23.2% from Q1 FY2025.
- Free cash flow was negative $13M in FY2025.
- Net loss narrowed to $23M in FY2025, from $52M in FY2024.
Computed from the as-reported figures in the statements below. A change we cannot state from filed figures is left out rather than estimated.
Peer comparison
Where Esperion Therapeutics’s fundamentals sit among the 198 pharmaceutical companies. Each figure is ranked only against peers that report it, from lowest (left) to highest (right).
No reported insider transactions (codes P/S) in the last 90 days. For context, about 15% of companies in the universe saw any reported insider purchase (code P) in the same window. Browse insider activity →
Percentiles describe where a figure sits among industry peers reporting it (100th = highest). They are position within a peer group, not a rating, and not investment advice. Short interest ranking uses days to cover from FINRA Consolidated Short Interest data; FINRA is the owner and source of that data, included at no additional charge.
Recent insider activity
Non-derivative buys and sells (codes P/S) reported by officers, directors and 10% owners on SEC Form 4.
| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
2026-06-17 filed 2026-06-18 | Sheldon L. KoenigPresident and CEO | Sell | 53.6K | $3.15 | $169K |
2026-06-17 filed 2026-06-18 | Benjamin LookerChief Legal Officer | Sell | 11.8K | $3.15 | $37K |
2026-06-17 filed 2026-06-18 | Benjamin HalladayChief Financial Officer | Sell | 10.8K | $3.15 | $34K |
Reported non-derivative purchases and sales (codes P/S), which may be open-market or private. Excludes option exercises, grants, and shares withheld for taxes. Dates shown are the trade date; a Form 4 can be filed days to years later. A sale can be routine (e.g. a pre-set 10b5-1 plan), so read individual transactions in context. From SEC Form 4. Not investment advice.
Short interest
Total shares sold short as of each twice-monthly FINRA settlement. Rising short interest means more investors are positioned against the stock; days to cover estimates how many trading days of average volume that position represents.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 2026-06-30 | 17.4M | -16.0% | 1.74 |
| 2026-06-15 | 20.7M | +10.7% | 1.76 |
| 2026-05-29 | 18.7M | -7.4% | 2.68 |
| 2026-05-15 | 20.2M | -44.5% | 1.00 |
| 2026-04-30 | 36.4M | +14.4% | 5.18 |
| 2026-04-15 | 31.8M | -3.9% | 3.73 |
| 2026-03-31 | 33.1M | -1.8% | 6.98 |
| 2026-03-13 | 33.7M | +0.6% | 5.05 |
Source: FINRA Consolidated Short Interest. FINRA is the owner and source of the FINRA-supplied data, which is included at no additional charge for your own personal or professional use; republishing or redistributing it is not permitted. Settlement dates are shown; FINRA publishes each settlement about nine business days later, so the latest figure can be two to four weeks old. Not presented as a percentage of float. No FINRA endorsement of this product is implied. Not investment advice.
Income statement (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $60.3M | $54.4M | $-155.6M | $-179.5M | $-226.7M |
| Net income | $-22.7M | $-51.7M | $-209.2M | $-233.7M | $-269.1M |
| Diluted EPS | $-0.11 | $-0.28 | $-2.03 | $-3.52 | $-9.31 |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Balance sheet (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Cash and equivalents | $167.9M | $144.8M | $82.2M | $124.8M | $208.9M |
| Current assets | $462.6M | $338.0M | $201.1M | $246.7M | $329.0M |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M |
| Current liabilities | $300.8M | $246.2M | $156.2M | $92.3M | $73.4M |
| Long-term debt | — | — | — | — | — |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M |
| Total equity | $-302.0M | $-388.7M | $-455.0M | $-323.8M | $-196.9M |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Cash flow (as reported)
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Operating cash flow | $-13.1M | $-23.7M | $-135.5M | $-174.8M | $-263.8M |
| Capital expenditure | $0 | $317,000 | $0 | $0 | $0 |
| Free cash flow |
Figures as reported to the SEC. Underlined values link to the filing they came from; dotted values are calculated by us from reported figures; “adj” means restated for a stock split (tap or hover a figure to see how it was calculated or what was filed). Full details: where the numbers come from.
Quarterly trend
| Quarter | Revenue | Revenue YoY | Net income | Diluted EPS |
|---|---|---|---|---|
| Q1 FY2026 | $80.1M | 23.2% | $-25.2M | $-0.10 |
| Q4 FY2025 | 143.7% | |||
| Q3 FY2025 | $87.3M | 69.1% | $-31.3M | $-0.16 |
| Q2 FY2025 | $82.4M | 11.6% | $-12.7M | $-0.06 |
| Q1 FY2025 | $65.0M | -52.8% | $-40.5M | $-0.21 |
| Q4 FY2024 | 114.3% | |||
| Q3 FY2024 | $51.6M | 52.0% | $-29.5M | $-0.15 |
| Q2 FY2024 | $73.8M | 186.3% | $-61.9M | $-0.33 |
Latest 8 quarters, from company XBRL filings on SEC EDGAR. A dotted underline marks a fourth-quarter figure we calculated from the full year and the first nine months. Revenue YoY is our calculation too: each quarter against the same quarter a year earlier.
Company facts
Selected SEC filings
Largest pharmaceutical peers
Monitor ESPR
Get an alert when Esperion Therapeutics files something material, see which superinvestors own it, and ask its filings a question with cited answers.
Monitor ESPR freeIncludes one free filing-grounded research answer. Or check your whole portfolio, no account needed.
Data sourced from SEC EDGAR. Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only. Not investment advice.